REGNRegeneron PharmaceuticalsSigning up patients
A Study to Investigate Mibavademab in Adult Women With Functional Hypothalamic Amenorrhea
Functional Hypothalamic Amenorrhea · FHA
5Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +4.8
5 insiders sold shares within a month
Since Nov 4, 2026 · was worth 5, fading over time
Worry score5
Score over time
- Stage
- Phase 2
- Patients
- 34 (planned)
- Started
- Mar 11, 2026
- Main results expected
- Jan 28, 2028
- Fully finished
- May 17, 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Change from the highest serum estradiol observed during a 28-day period
Measured over: Baseline to month 6
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 4.8, since 2026-11-04, fades (half-life)
Raw record changes
- none yet
Trial ID NCT07235917 · record last updated 2026-11-04 · checked 2026-11-09 15:47 UTC